<!doctype html><html lang=zh-tw><head><meta charset=utf-8><meta name=description content="Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer ÊûóÂçîÈúÜ, Fellow 1    HER2-low Breast Cancer Overview  60% HER2- metastatic BC express low HER2 levels HER2-low: Def."><meta property="og:title" content><meta property="og:description" content><meta property="og:type" content="website"><meta property="og:url" content><meta property="og:image" content="https://og-mlkgi530p-htlin222.vercel.app/api/blog?templateTitle=Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer"><title>Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer</title><meta name=viewport content="width=device-width,initial-scale=1"><link rel=alternate type=application/rss+xml href=https://www.physician.tw//feed.xml title><link rel="shortcut icon" type=image/png href=https://www.physician.tw//icon.png><link href=https://www.physician.tw/styles.720e2c4835986a3891d6eef3a55faa22.min.css rel=stylesheet><link href=https://www.physician.tw/styles/_light_syntax.86a48a52faebeaaf42158b72922b1c90.min.css rel=stylesheet id=theme-link><script src=https://www.physician.tw/js/darkmode.dfadb738e747a87e78c7144d7267f1bc.min.js></script>
<script src=https://www.physician.tw/js/util.6f22941e242efae60fd84e7c32e874fa.min.js></script>
<link rel=preload href=https://cdn.jsdelivr.net/npm/katex@0.15.1/dist/katex.min.css as=style onload='this.onload=null,this.rel="stylesheet"' integrity=sha384-R4558gYOUz8mP9YWpZJjofhk+zx0AS11p36HnD2ZKj/6JR5z27gSSULCNHIRReVs crossorigin=anonymous><script defer src=https://cdn.jsdelivr.net/npm/katex@0.15.1/dist/katex.min.js integrity=sha384-z1fJDqw8ZApjGO3/unPWUPsIymfsJmyrDVWC8Tv/a1HeOtGmkwNd/7xUS0Xcnvsx crossorigin=anonymous></script>
<script defer src=https://cdn.jsdelivr.net/npm/katex@0.15.1/dist/contrib/auto-render.min.js integrity=sha384-+XBljXPPiv+OzfbB3cVmLHf4hdUFHlWNZN5spNQ7rmHTXpd7WvJum6fIACpNNfIR crossorigin=anonymous></script>
<script defer src=https://cdn.jsdelivr.net/npm/katex@0.16.2/dist/contrib/copy-tex.min.js integrity=sha384-ww/583aHhxWkz5DEVn6OKtNiIaLi2iBRNZXfJRiY1Ai7tnJ9UXpEsyvOITVpTl4A crossorigin=anonymous></script>
<script async src=https://unpkg.com/@floating-ui/core@0.7.3></script>
<script async src=https://unpkg.com/@floating-ui/dom@0.5.4></script>
<script async src=https://www.physician.tw/js/popover.f03552ccb84d99ca615d1cfb9abde59e.min.js></script>
<script defer src=https://www.physician.tw/js/code-title.ce4a43f09239a9efb48fee342e8ef2df.min.js></script>
<script defer src=https://www.physician.tw/js/clipboard.2913da76d3cb21c5deaa4bae7da38c9f.min.js></script>
<script defer src=https://www.physician.tw/js/callouts.7723cac461d613d118ee8bb8216b9838.min.js></script>
<script>const SEARCH_ENABLED=!1,LATEX_ENABLED=!0,PRODUCTION=!0,BASE_URL="https://www.physician.tw/",fetchData=Promise.all([fetch("https://www.physician.tw/indices/linkIndex.440c12afe56c47722e71383f56d9f8f0.min.json").then(e=>e.json()).then(e=>({index:e.index,links:e.links})),fetch("https://www.physician.tw/indices/contentIndex.9d824aa930866f2c31941e3db882301d.min.json").then(e=>e.json())]).then(([{index:e,links:t},n])=>({index:e,links:t,content:n})),render=()=>{const e=new URL(BASE_URL),t=e.pathname,n=window.location.pathname,s=t==n;addCopyButtons(),addTitleToCodeBlocks(),addCollapsibleCallouts(),initPopover("https://www.physician.tw",!0);const o=document.getElementById("footer");if(o){const e=document.getElementById("graph-container");if(!e)return requestAnimationFrame(render);e.textContent="";const t=s&&!1;drawGraph("https://www.physician.tw",t,[{"/moc":"#4388cc"}],t?{centerForce:1,depth:-1,enableDrag:!0,enableLegend:!1,enableZoom:!0,fontSize:.5,linkDistance:1,opacityScale:3,repelForce:1,scale:1.4}:{centerForce:1,depth:1,enableDrag:!0,enableLegend:!1,enableZoom:!0,fontSize:.6,linkDistance:1,opacityScale:3,repelForce:2,scale:1.2})}},init=(e=document)=>{addCopyButtons(),addTitleToCodeBlocks(),renderMathInElement(e.body,{delimiters:[{left:"$$",right:"$$",display:!0},{left:"$",right:"$",display:!1}],macros:{'‚Äô':"'"},throwOnError:!1})}</script><script type=module>
    import { attachSPARouting } from "https:\/\/www.physician.tw\/js\/router.9d4974281069e9ebb189f642ae1e3ca2.min.js"
    attachSPARouting(init, render)
  </script></head><body><div id=search-container><div id=search-space><input autocomplete=off id=search-bar name=search type=text aria-label=ÊêúÂ∞ã placeholder="Ë´ãËº∏ÂÖ•ÂÉèÊòØÔºöhypertension ‰πãÈ°ûÁöÑ‰æÜÁúãÊ≤íÊúâÊ≤í‰ªÄÈ∫ºÊúâË∂£ÁöÑüé≥"><div id=results-container></div></div></div><script src=https://cdn.jsdelivr.net/npm/flexsearch@0.7.21/dist/flexsearch.bundle.js integrity="sha256-i3A0NZGkhsKjVMzFxv3ksk0DZh3aXqu0l49Bbh0MdjE=" crossorigin=anonymous defer></script>
<script defer src=https://www.physician.tw/js/full-text-search.e6e2e0c213187ca0c703d6e2c7a77fcd.min.js></script><div class=singlePage><header><h1 id=page-title><a href=https://www.physician.tw/>Ëú•Ëú¥Ëä±Âúíü¶éüå±ü™¥üå≤</a></h1><div class=spacer></div><div id=search-icon><p>ÊêúÂ∞ã</p><svg tabindex="0" aria-labelledby="title desc" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 19.9 19.7"><title id="title">ÊêúÂ∞ãÂúñÁ§∫</title><desc id="desc">ÊâìÈñãÊêúÂ∞ãÂúñÊ®ô</desc><g class="search-path" fill="none"><path stroke-linecap="square" d="M18.5 18.3l-5.4-5.4"/><circle cx="8" cy="8" r="7"/></g></svg></div><div class=darkmode><input class=toggle id=darkmode-toggle type=checkbox tabindex=-1>
<label id=toggle-label-light for=darkmode-toggle tabindex=-1><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" id="dayIcon" viewBox="0 0 35 35" style="enable-background:new 0 0 35 35"><title>Êòé‰∫ÆÊ®°Âºè</title><path d="M6 17.5C6 16.672 5.328 16 4.5 16h-3C.672 16 0 16.672.0 17.5S.672 19 1.5 19h3C5.328 19 6 18.328 6 17.5zM7.5 26c-.414.0-.789.168-1.061.439l-2 2C4.168 28.711 4 29.086 4 29.5 4 30.328 4.671 31 5.5 31c.414.0.789-.168 1.06-.44l2-2C8.832 28.289 9 27.914 9 27.5 9 26.672 8.329 26 7.5 26zm10-20C18.329 6 19 5.328 19 4.5v-3C19 .672 18.329.0 17.5.0S16 .672 16 1.5v3C16 5.328 16.671 6 17.5 6zm10 3c.414.0.789-.168 1.06-.439l2-2C30.832 6.289 31 5.914 31 5.5 31 4.672 30.329 4 29.5 4c-.414.0-.789.168-1.061.44l-2 2C26.168 6.711 26 7.086 26 7.5 26 8.328 26.671 9 27.5 9zM6.439 8.561C6.711 8.832 7.086 9 7.5 9 8.328 9 9 8.328 9 7.5c0-.414-.168-.789-.439-1.061l-2-2C6.289 4.168 5.914 4 5.5 4 4.672 4 4 4.672 4 5.5c0 .414.168.789.439 1.06l2 2.001zM33.5 16h-3c-.828.0-1.5.672-1.5 1.5s.672 1.5 1.5 1.5h3c.828.0 1.5-.672 1.5-1.5S34.328 16 33.5 16zM28.561 26.439C28.289 26.168 27.914 26 27.5 26c-.828.0-1.5.672-1.5 1.5.0.414.168.789.439 1.06l2 2C28.711 30.832 29.086 31 29.5 31c.828.0 1.5-.672 1.5-1.5.0-.414-.168-.789-.439-1.061l-2-2zM17.5 29c-.829.0-1.5.672-1.5 1.5v3c0 .828.671 1.5 1.5 1.5s1.5-.672 1.5-1.5v-3C19 29.672 18.329 29 17.5 29zm0-22C11.71 7 7 11.71 7 17.5S11.71 28 17.5 28 28 23.29 28 17.5 23.29 7 17.5 7zm0 18c-4.136.0-7.5-3.364-7.5-7.5s3.364-7.5 7.5-7.5 7.5 3.364 7.5 7.5S21.636 25 17.5 25z"/></svg></label><label id=toggle-label-dark for=darkmode-toggle tabindex=-1><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" id="nightIcon" viewBox="0 0 100 100" style="enable-background='new 0 0 100 100'"><title>ÈªëÊöóÊ®°Âºè</title><path d="M96.76 66.458c-.853-.852-2.15-1.064-3.23-.534-6.063 2.991-12.858 4.571-19.655 4.571C62.022 70.495 50.88 65.88 42.5 57.5 29.043 44.043 25.658 23.536 34.076 6.47c.532-1.08.318-2.379-.534-3.23-.851-.852-2.15-1.064-3.23-.534-4.918 2.427-9.375 5.619-13.246 9.491-9.447 9.447-14.65 22.008-14.65 35.369.0 13.36 5.203 25.921 14.65 35.368s22.008 14.65 35.368 14.65c13.361.0 25.921-5.203 35.369-14.65 3.872-3.871 7.064-8.328 9.491-13.246C97.826 68.608 97.611 67.309 96.76 66.458z"/></svg></label></div></header><article><h1>Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer</h1><p class=meta>ÊúÄÂæåÊõ¥Êñ∞Êñº
Aug 28, 2023
<a href=https://github.com/htlin222/garden/tree/hugo/content/slides/Trastuzumab%20Deruxtecan%20in%20Previously%20Treated%20HER2-Low%20Advanced%20Breast%20Cancer.md rel=noopener>ü™ö Á∑®ËºØÂéüÂßãÊñá‰ª∂</a></p><ul class=tags></ul><aside class=mainTOC><details><summary>üìíÁõÆÈåÑ</summary><nav id=TableOfContents><ol><li><a href=#ÊûóÂçîÈúÜ-fellow-1>ÊûóÂçîÈúÜ, Fellow 1</a></li><li><a href=#her2-low-breast-cancer-overview>HER2-low Breast Cancer Overview</a></li><li><a href=#mechanism-of-action-of-agents-targeting-her2>Mechanism of action of agents targeting HER2</a></li><li><a href=#novel-antibody-drug-conjugates-and-her2-low-breast-cancer>Novel Antibody-Drug Conjugates and HER2-Low Breast Cancer</a></li><li><a href=#proposal-of-an-algorithm-for-defining-her2-low-bc>Proposal of an algorithm for defining HER2-low BC</a></li><li><a href=#novel-agents-and-mechanisms-enabling-the-targeting-of-her2-lowexpressing-bc>Novel agents and mechanisms enabling the targeting of HER2-low‚Äìexpressing BC</a></li><li><a href=#trastuzumab-and-adjuvant-chemotherapy-in-her2-negative-breast-cancer>Trastuzumab and Adjuvant Chemotherapy in HER2-Negative Breast Cancer</a><ol><li></li></ol></li><li><a href=#treatment-options-for-her2-negative-metastatic-breast-cancer>Treatment Options for HER2-negative Metastatic Breast Cancer</a></li><li><a href=#palbociclib-and-letrozole-in-breast-cancer>Palbociclib and Letrozole in Breast Cancer</a></li><li><a href=#sacituzumab-govitecan-in-breast-cancer>Sacituzumab Govitecan in Breast Cancer</a></li><li><a href=#trastuzumab-deruxtecan-for-her2-low-metastatic-breast-cancer>Trastuzumab Deruxtecan for HER2-Low Metastatic Breast Cancer</a></li><li><a href=#trastuzumab-deruxtecan-in-previously-treated-her2-positive-breast-cancer>Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer</a></li><li><a href=#trastuzumab-deruxtecan-vs-trastuzumab-emtansine-in-breast-cancer>Trastuzumab Deruxtecan v.s. Trastuzumab Emtansine in Breast Cancer</a></li><li><a href=#t-dxd-vs-t-dm1>T-Dxd v.s T-Dm1</a></li><li><a href=#back-to-our-study>Back to Our Study</a></li><li><a href=#methods>Methods</a></li><li><a href=#trial-design>Trial Design</a></li><li><a href=#her2-expression-testing>HER2 Expression Testing</a></li><li><a href=#patient-eligibility-criteria>Patient Eligibility Criteria</a></li><li><a href=#treatment-administration>Treatment Administration</a></li><li><a href=#end-points>End Points</a></li><li><a href=#safety>Safety</a></li><li><a href=#results>Results</a></li><li><a href=#patient-enrollment-and-characteristics>Patient Enrollment and Characteristics</a></li><li><a href=#efficacy>Efficacy</a></li><li><a href=#figure-1a>Figure 1A</a></li><li><a href=#overall-efficacy>Overall Efficacy</a></li><li><a href=#overall-survival>Overall Survival</a></li><li><a href=#objective-response-rate>Objective Response Rate</a></li><li><a href=#objective-response-rate-all-patients>Objective Response Rate (All Patients)</a></li><li><a href=#safety-analysis>Safety Analysis</a></li><li><a href=#adverse-events>Adverse Events</a></li><li><a href=#drug-related-adverse-events>Drug-related Adverse Events</a></li><li><a href=#drug-related-interstitial-lung-disease-or-pneumonitis>Drug-related Interstitial Lung Disease or Pneumonitis</a></li><li><a href=#kaplane-meier-analysis-of-time-to-first-adjudicated-drug-related-ildpneumonitis-event>Kaplane Meier analysis of time to first adjudicated drug-related ILD/pneumonitis event</a></li><li><a href=#multivariate-stepwise-cox-regression-analysis>Multivariate stepwise Cox regression analysis</a></li><li><a href=#left-ventricular-dysfunction>Left Ventricular Dysfunction</a></li><li><a href=#discussion>Discussion</a></li><li><a href=#trastuzumab-deruxtecan-vs-chemotherapy>Trastuzumab Deruxtecan vs. Chemotherapy</a></li><li><a href=#her2-status-and-trastuzumab-deruxtecan>HER2 Status and Trastuzumab Deruxtecan</a></li><li><a href=#trastuzumab-deruxtecan-in-hormone-receptor-positive-her2-negative-breast-cancer>Trastuzumab Deruxtecan in Hormone Receptor-Positive, HER2-Negative Breast Cancer</a></li><li><a href=#trastuzumab-deruxtecan-vs-sacituzumab-govitecan>Trastuzumab Deruxtecan vs. Sacituzumab Govitecan</a></li><li><a href=#safety-profile-of-trastuzumab-deruxtecan>Safety Profile of Trastuzumab Deruxtecan</a></li><li><a href=#interstitial-lung-disease-or-pneumonitis-risk-with-trastuzumab-deruxtecan>Interstitial Lung Disease or Pneumonitis Risk with Trastuzumab Deruxtecan</a></li><li><a href=#her2-low-status-and-trastuzumab-deruxtecan>HER2-Low Status and Trastuzumab Deruxtecan</a></li><li><a href=#conclusion-trastuzumab-deruxtecan-vs-physicians-choice-of-chemotherapy>Conclusion: Trastuzumab Deruxtecan vs. Physician&rsquo;s Choice of Chemotherapy</a></li><li><a href=#the-end>THE END</a></li></ol></nav></details></aside><a href=#trastuzumab-deruxtecan-in-previously-treated-her2-low-advanced-breast-cancer><h1 id=trastuzumab-deruxtecan-in-previously-treated-her2-low-advanced-breast-cancer><span class=hanchor arialabel=Anchor># </span>Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer</h1></a><a href=#ÊûóÂçîÈúÜ-fellow-1><h2 id=ÊûóÂçîÈúÜ-fellow-1><span class=hanchor arialabel=Anchor># </span>ÊûóÂçîÈúÜ, Fellow 1</h2></a><hr><p><img src=https://i.imgur.com/QCErHHs.png width=auto alt="Figure: bg height:550px"></p><hr><a href=#her2-low-breast-cancer-overview><h2 id=her2-low-breast-cancer-overview><span class=hanchor arialabel=Anchor># </span>HER2-low Breast Cancer Overview</h2></a><ul><li>60% HER2- metastatic BC express low HER2 levels</li><li>HER2-low: Def. 1+ on IHC or 2+ IHC score with negative ISH results</li><li>Current HER2-directed therapies have not improved outcomes</li><li>HER2-low treated as HER2-negative</li><li>Limited targeted treatment options after progression during primary therapy</li><li>Single-agent palliative chemotherapy is common.</li></ul><p><img src=https://i.imgur.com/ih2DMpd.png width=auto alt="Figure: width:950px"></p><hr><p><img src=https://i.imgur.com/W3PbL8G.jpg width=auto alt="Figure: bg height:650px"></p><blockquote><p>Oh DY, Bang YJ. HER2-targeted therapies ‚Äî a role beyond breast cancer. Nat Rev Clin Oncol. 2020;17(1):33-48. doi:10.1038/s41571-019-0268-3</p></blockquote><hr><a href=#mechanism-of-action-of-agents-targeting-her2><h2 id=mechanism-of-action-of-agents-targeting-her2><span class=hanchor arialabel=Anchor># </span>Mechanism of action of agents targeting HER2</h2></a><p><img src=https://i.imgur.com/pj6ZJTT.jpg width=auto alt="Figure: bg height:550px"></p><blockquote><p>Oh DY, Bang YJ. HER2-targeted therapies ‚Äî a role beyond breast cancer. Nat Rev Clin Oncol. 2020;17(1):33-48. doi:10.1038/s41571-019-0268-3</p></blockquote><hr><a href=#novel-antibody-drug-conjugates-and-her2-low-breast-cancer><h2 id=novel-antibody-drug-conjugates-and-her2-low-breast-cancer><span class=hanchor arialabel=Anchor># </span>Novel Antibody-Drug Conjugates and HER2-Low Breast Cancer</h2></a><ul><li>HER2-low was higher in <strong>HR-positive disease</strong> (65.4%) than triple-negative BC (TNBC, 36.6%)</li><li>HR-positive:<ul><li><strong>ERBB2</strong> and luminal-related genes were more expressed in HER2-low than HER2 0,</li></ul></li><li>Within HER2-low, ERBB2 levels were higher in HR-positive disease than TNBC</li><li>HER2-low was not associated with overall survival in HR-positive disease and TNBC</li><li>The reproducibility of HER2-low among pathologists was suboptimal</li><li><strong>large biological heterogeneity of HER2-low BC and the need to implement reproducible and sensitive assays to measure low HER2 expression.</strong></li></ul><blockquote><p>Schettini F, Chic N, Bras√≥-Maristany F, et al. Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer. NPJ Breast Cancer 2021;7:1-1.</p></blockquote><hr><p><img src=https://i.imgur.com/jbIuiYK.png width=auto alt="Figure: bg height:550px"></p><hr><p><img src=https://i.imgur.com/pcofx8V.png width=auto alt="Figure: bg height:650px"></p><hr><a href=#proposal-of-an-algorithm-for-defining-her2-low-bc><h2 id=proposal-of-an-algorithm-for-defining-her2-low-bc><span class=hanchor arialabel=Anchor># </span>Proposal of an algorithm for defining HER2-low BC</h2></a><p><img src=https://i.imgur.com/tPQ9n5U.png width=auto alt="Figure: height:550px"></p><blockquote><p>Tarantino P, Hamilton E, Tolaney SM, et al. HER2-low breast cancer: pathological and clinical landscape. J Clin Oncol 2020;38:1951-1962.</p></blockquote><hr><a href=#novel-agents-and-mechanisms-enabling-the-targeting-of-her2-lowexpressing-bc><h2 id=novel-agents-and-mechanisms-enabling-the-targeting-of-her2-lowexpressing-bc><span class=hanchor arialabel=Anchor># </span>Novel agents and mechanisms enabling the targeting of HER2-low‚Äìexpressing BC</h2></a><p><img src=https://i.imgur.com/WtthcG7.jpg width=auto alt="Figure: height:480px"></p><blockquote><p>Tarantino P, Hamilton E, Tolaney SM, et al. HER2-low breast cancer: pathological and clinical landscape. J Clin Oncol 2020;38:1951-1962.</p></blockquote><hr><a href=#trastuzumab-and-adjuvant-chemotherapy-in-her2-negative-breast-cancer><h2 id=trastuzumab-and-adjuvant-chemotherapy-in-her2-negative-breast-cancer><span class=hanchor arialabel=Anchor># </span>Trastuzumab and Adjuvant Chemotherapy in HER2-Negative Breast Cancer</h2></a><ul><li><strong>NSABP B-47 trial</strong></li><li>3,270 women with high-risk primary IBC were randomly assigned to CRx with or without <strong>1 year of trastuzumab</strong></li><li><strong>HER2-negative</strong> breast cancer</li><li>At a median follow-up of 46 months:<ul><li>Did <code>NOT</code> improve IDFS, distant recurrence-free interval, or OS</li></ul></li></ul><a href=#note><h5 id=note><span class=hanchor arialabel=Anchor># </span>Note</h5></a><ul><li>Trastuzumab does not benefit women without IHC 3+ or FISH ratio-amplified breast cancer</li></ul><blockquote><p>Fehrenbacher L, Cecchini RS, Geyer CE Jr, et al. NSABP B-47/NRG oncology phase III randomized trial comparing adjuvant chemotherapy with or without trastuzumab in high-risk invasive breast cancer negative for HER2 by FISH and with IHC 1+ or 2. J Clin Oncol 2020;38:444-453.</p></blockquote><hr><a href=#treatment-options-for-her2-negative-metastatic-breast-cancer><h2 id=treatment-options-for-her2-negative-metastatic-breast-cancer><span class=hanchor arialabel=Anchor># </span>Treatment Options for HER2-negative Metastatic Breast Cancer</h2></a><ul><li>For hormone receptor-positive, HER2-negative metastatic disease, endocrine therapy and CDK4/6 inhibitors are effective for ~2 years</li><li>Resistance often occurs after 2 years</li><li>Real-world data show a low progression-free survival with systemic therapies after CDK4/6 inhibitors and chemotherapy in metastatic disease</li><li>For hormone receptor-negative, HER2-negative metastatic disease, few targeted agents are available</li><li>Limited options for patients without pathogenic BRCA mutations or tumors without programmed death ligand 1 expression.</li></ul><hr><a href=#palbociclib-and-letrozole-in-breast-cancer><h2 id=palbociclib-and-letrozole-in-breast-cancer><span class=hanchor arialabel=Anchor># </span>Palbociclib and Letrozole in Breast Cancer</h2></a><ul><li>median progression-free survival was 24.8 months in the palbociclib‚Äìletrozole group compared to 14.5 months in the placebo‚Äìletrozole group</li><li>The hazard ratio for disease progression or death was 0.58 (95% CI, 0.46 to 0.72; P&lt;0.001)</li><li>Permanent discontinuation of any study treatment as a result of adverse events occurred in 9.7% of patients in the palbociclib‚Äìletrozole group and 5.9% in the placebo‚Äìletrozole group.</li></ul><blockquote><p>Finn RS, Martin M, Rugo HS, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med 2016;375:1925-1936.</p></blockquote><hr><a href=#sacituzumab-govitecan-in-breast-cancer><h2 id=sacituzumab-govitecan-in-breast-cancer><span class=hanchor arialabel=Anchor># </span>Sacituzumab Govitecan in Breast Cancer</h2></a><ul><li>468 pt w/o brain metastases, RCT</li><li>The median progression-free survival was 5.6 months with sacituzumab govitecan and 1.7 months with chemotherapy</li><li>The hazard ratio for disease progression or death was 0.41 (95% CI, 0.32 to 0.52; P&lt;0.001)</li><li>The median overall survival was 12.1 months with sacituzumab govitecan and 6.7 months with chemotherapy</li></ul><blockquote><p>Bardia A, Hurvitz SA, Tolaney SM, et al. Sacituzumab govitecan in metastatic triple-negative breast cancer. N Engl J Med 2021;384:1529-1541.</p></blockquote><hr><p><img src=https://i.imgur.com/tf4DAYf.png width=auto alt="Figure: bg height:640px"></p><blockquote><p>Bardia A, Hurvitz SA, Tolaney SM, et al. Sacituzumab govitecan in metastatic triple-negative breast cancer. N Engl J Med 2021;384:1529-1541.</p></blockquote><hr><a href=#trastuzumab-deruxtecan-for-her2-low-metastatic-breast-cancer><h2 id=trastuzumab-deruxtecan-for-her2-low-metastatic-breast-cancer><span class=hanchor arialabel=Anchor># </span>Trastuzumab Deruxtecan for HER2-Low Metastatic Breast Cancer</h2></a><ul><li>antibody-drug conjugate for metastatic HER2-positive breast cancer</li><li>Can target tumor cells w/ low HER2 levels and deliver potent <strong>cytotoxic payload</strong></li><li>Trastuzumab deruxtecan more effective than available treatments for triple-negative or endocrine-refractory hormone receptor-positive breast cancer</li><li>Phase 3 clinical trial (DESTINY-Breast04) evaluated trastuzumab deruxtecan efficacy and safety vs. physician&rsquo;s choice of chemotherapy in HER2-low metastatic breast cancer.</li></ul><hr><a href=#trastuzumab-deruxtecan-in-previously-treated-her2-positive-breast-cancer><h2 id=trastuzumab-deruxtecan-in-previously-treated-her2-positive-breast-cancer><span class=hanchor arialabel=Anchor># </span>Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer</h2></a><ul><li>184 patients who had undergone a median of six previous treatments received the recommended dose of trastuzumab deruxtecan (5.4 mg per kilogram of body weight)</li><li>In the intention-to-treat analysis, a response to therapy was reported in 112 patients (60.9%; 95% CI, 53.4 to 68.0)</li><li>The median duration of follow-up was 11.1 months, the median response duration was 14.8 months, and the median duration of progression-free survival was 16.4 months</li><li>The most common adverse events of grade 3 or higher were a decreased neutrophil count (20.7%), anemia (8.7%), and nausea (7.6%)</li><li>On independent adjudication, the trial drug was associated with interstitial lung disease in 13.6% of the patients (grade 1 or 2, 10.9%; grade 3 or 4, 0.5%; and grade 5, 2.2%)</li></ul><blockquote><p>Modi S, Saura C, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med 2020;382:610-621.</p></blockquote><hr><a href=#trastuzumab-deruxtecan-vs-trastuzumab-emtansine-in-breast-cancer><h2 id=trastuzumab-deruxtecan-vs-trastuzumab-emtansine-in-breast-cancer><span class=hanchor arialabel=Anchor># </span>Trastuzumab Deruxtecan v.s. Trastuzumab Emtansine in Breast Cancer</h2></a><ul><li>Among 524 randomly assigned patients, trastuzumab deruxtecan showed a superior percentage of patients who were alive without disease progression at 12 months compared to trastuzumab emtansine (75.8% vs. 34.1%)</li><li>The hazard ratio for progression or death from any cause was 0.28 (95% CI, 0.22 to 0.37; P&lt;0.001)</li><li>The percentage of patients who were alive at 12 months was higher with trastuzumab deruxtecan compared to trastuzumab emtansine (94.1% vs. 85.9%)</li><li>The hazard ratio for death was 0.55 (95% CI, 0.36 to 0.86; prespecified significance boundary not reached)</li><li>An overall response occurred in 79.7% of the patients who received trastuzumab deruxtecan and 34.2% of those who received trastuzumab emtansine</li></ul><blockquote><p>Cort√©s J, Kim S-B, Chung W-P, et al. Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer. N Engl J Med 2022;386:1143-1154.</p></blockquote><hr><p><img src=https://i.imgur.com/UE5J8xD.png width=auto alt="Figure: bg height:600px"></p><blockquote><p>Cort√©s J, Kim S-B, Chung W-P, et al. Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer. N Engl J Med 2022;386:1143-1154.</p></blockquote><hr><a href=#t-dxd-vs-t-dm1><h2 id=t-dxd-vs-t-dm1><span class=hanchor arialabel=Anchor># </span>T-Dxd v.s T-Dm1</h2></a><ul><li><p>The incidence of drug-related adverse events of any grade was</p><ul><li><strong>higher</strong> with trastuzumab deruxtecan compared to trastuzumab emtansine (98.1% vs. 86.6%),</li></ul></li><li><p>incidence of drug-related adverse events of grade 3 or 4 was similar</p><ul><li>between the two groups (45.1% and 39.8%)</li></ul></li><li><p>Adjudicated drug-related interstitial lung disease or pneumonitis</p><ul><li>occurred in 10.5% of the patients in the trastuzumab deruxtecan group and</li><li>1.9% of those in the trastuzumab emtansine group;</li><li>none of these events were of grade 4 or 5.</li></ul></li></ul><blockquote><p>Cort√©s J, Kim S-B, Chung W-P, et al. Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer. N Engl J Med 2022;386:1143-1154.</p></blockquote><hr><style scoped>h2{font-size:7em;font-weight:800}section{display:flex;justify-content:center;align-items:center}</style><a href=#back-to-our-study><h2 id=back-to-our-study><span class=hanchor arialabel=Anchor># </span>Back to Our Study</h2></a><hr><style scoped>h2{font-size:6em;font-weight:700}section{display:flex;justify-content:center;align-items:center}</style><a href=#methods><h2 id=methods><span class=hanchor arialabel=Anchor># </span>Methods</h2></a><hr><a href=#trial-design><h2 id=trial-design><span class=hanchor arialabel=Anchor># </span>Trial Design</h2></a><ul><li>Randomized, two-group, open-label phase 3 trial</li><li>patients with <strong>HER2-low</strong>, unresectable or metastatic breast cancer</li><li>Enrollment planned for <em>480</em> hormone receptor-positive patients and 60 hormone receptor-negative patients</li><li>Patients randomly assigned to<ul><li>trastuzumab deruxtecan</li><li>or physician&rsquo;s choice of capecitabine, eribulin, gemcitabine, paclitaxel, or nab-paclitaxel</li></ul></li><li>Randomization stratified according to<ul><li>HER2-low status</li><li>number of previous chemotherapy lines for metastatic disease, and hormone-receptor status</li></ul></li><li>Aim: trastuzumab deruxtecan efficacy and safety</li></ul><hr><a href=#her2-expression-testing><h2 id=her2-expression-testing><span class=hanchor arialabel=Anchor># </span>HER2 Expression Testing</h2></a><ul><li>IHC scores for HER2 expression determined through central testing of tumor-biopsy specimens</li></ul><p><img src=https://i.imgur.com/9LklVdm.png width=auto alt="Figure: height:450px"></p><blockquote><p>Algorithm adapted from 2018 ASCO-CAP testing guidelines</p></blockquote><hr><a href=#patient-eligibility-criteria><h2 id=patient-eligibility-criteria><span class=hanchor arialabel=Anchor># </span>Patient Eligibility Criteria</h2></a><ul><li>as 2L for pt:<ul><li>received chemotherapy for metastatic disease</li><li>disease recurrence within 6 months after completing adjuvant chemotherapy</li></ul></li><li>Hormone receptor-positive patients must have received at least one line of endocrine therapy</li><li>Patients with treated, stable brain metastases were eligible</li><li>Patients ineligible if had a history of<ul><li>noninfectious <strong>interstitial lung disease</strong> treated with glucocorticoids or suspected interstitial lung disease on imaging at screening.</li></ul></li></ul><hr><a href=#treatment-administration><h2 id=treatment-administration><span class=hanchor arialabel=Anchor># </span>Treatment Administration</h2></a><ul><li>Trastuzumab deruxtecan administered intravenously every 3 weeks</li><li>Dose: 5.4 mg per kilogram of body weight</li><li>Physician&rsquo;s choice of chemotherapy administered according to local label or NCCN guidelines.</li></ul><p>:::columns</p><p><img src=https://i.imgur.com/dd2Pkf6.png width=auto alt="Figure: height:350px"></p><p>:::split</p><ul><li>100mg/vial</li><li><del>Èô¢ÂÖßËá™Ë≤ªÂÉπÊ†º 72080</del></li></ul><p>:::</p><hr><a href=#end-points><h2 id=end-points><span class=hanchor arialabel=Anchor># </span>End Points</h2></a><ul><li>PFS and response to treatment assessed by blinded independent central review</li><li>Primary end point:<ul><li>PFS in patients with hormone receptor-positive disease</li></ul></li><li>Key secondary end points:<ul><li>Progression-free survival in all patients and overall survival in hormone receptor-positive cohort and among all patients</li></ul></li><li>Secondary and other end points: Investigator-assessed progression-free survival, confirmed objective response, duration of response, and efficacy in hormone receptor-negative cohort.</li></ul><hr><a href=#safety><h2 id=safety><span class=hanchor arialabel=Anchor># </span>Safety</h2></a><ul><li>Adverse events coded and graded according to Medical Dictionary for Regulatory Activities (version 24.0) and National Cancer Institute Common Terminology Criteria for Adverse Events (version 5.0)</li><li>Potential cases of interstitial lung disease or pneumonitis evaluated by independent adjudication committee</li><li>Protocol-specified guidelines on management of interstitial lung disease and pneumonitis provided in Table S2.</li></ul><hr><style scoped>h2{font-size:9em;font-weight:700}section{display:flex;justify-content:center;align-items:center}</style><a href=#results><h2 id=results><span class=hanchor arialabel=Anchor># </span>Results</h2></a><hr><p><img src=https://i.imgur.com/9nZRbIF.png width=auto alt="bg Figure: height:720px"></p><hr><p><img src=https://i.imgur.com/idvzDUc.png width=auto alt="bg Figure: height:720px"></p><hr><a href=#patient-enrollment-and-characteristics><h2 id=patient-enrollment-and-characteristics><span class=hanchor arialabel=Anchor># </span>Patient Enrollment and Characteristics</h2></a><ul><li>713 patients<ul><li>with HER2-low metastatic breast cancer screened for potential trial entry from December 27, 2018, through December 31, 2021</li></ul></li><li>373 patients<ul><li>randomly assigned to trastuzumab deruxtecan group and 184 patients assigned to physician&rsquo;s choice group</li></ul></li><li>331 (88.7%) patients<ul><li>trastuzumab deruxtecan group and</li></ul></li><li>163 (88.6%) patients<ul><li>in physician&rsquo;s choice group comprised hormone receptor-positive cohort</li></ul></li></ul><hr><ul><li>In physician&rsquo;s choice group, patients received<ul><li>eribulin (51.1%),</li><li>capecitabine (20.1%),</li><li>nab-paclitaxel (10.3%),</li><li>gemcitabine (10.3%),</li><li>or paclitaxel (8.2%)</li></ul></li><li>Patients in both groups had median of three lines of treatment for metastatic disease</li><li>Median duration of follow-up for survival was<ul><li>18.4 months (95% confidence interval [CI], 17.7 to 18.9).</li></ul></li></ul><hr><a href=#efficacy><h2 id=efficacy><span class=hanchor arialabel=Anchor># </span>Efficacy</h2></a><ul><li>Median progression-free survival in hormone receptor-positive cohort was<ul><li>10.1 months (95% CI, 9.5 to 11.5) in trastuzumab deruxtecan group</li><li>5.4 months (95% CI, 4.4 to 7.1) in physician&rsquo;s choice group at primary efficacy analysis data-cutoff date (January 11, 2022)</li></ul></li><li>Hazard ratio for disease progression or death<ul><li>0.51 (95% CI, 0.40 to 0.64; P&lt;0.001) in favor of trastuzumab deruxtecan group (Figure 1A and Table 2)</li></ul></li></ul><hr><p><img src=https://i.imgur.com/ZHVCVYE.png width=auto alt="Figure: bg height:650px"></p><hr><ul><li>Consistent benefit observed for trastuzumab deruxtecan across analyzed subgroups (Fig. S2)</li><li>Median progression-free survival in trastuzumab deruxtecan group was<ul><li>10.3 months among patients with HER2 IHC score of 1+</li><li>10.1 months among those with HER2 IHC score of 2+ and negative results on ISH</li></ul></li><li>Among patients who had received previous treatment with CDK4/6 inhibitors:<ul><li>median progression-free survival was 10.0 months in trastuzumab deruxtecan group; without previous CDK4/6 inhibitor treatment, it was 11.7 months.</li></ul></li></ul><hr><a href=#figure-1a><h2 id=figure-1a><span class=hanchor arialabel=Anchor># </span>Figure 1A</h2></a><p><img src=https://i.imgur.com/jtAY6lu.png width=auto alt="Figure 1A: height:350px"></p><hr><hr><a href=#overall-efficacy><h2 id=overall-efficacy><span class=hanchor arialabel=Anchor># </span>Overall Efficacy</h2></a><ul><li>Median progression-free survival among all patients was<ul><li>9.9 months (95% CI, 9.0 to 11.3) in trastuzumab deruxtecan group and</li><li>5.1 months (95% CI, 4.2 to 6.8) in physician&rsquo;s choice group</li></ul></li><li>Hazard ratio for disease progression or death<ul><li>0.50 (95% CI, 0.40 to 0.63; P&lt;0.001) in favor of trastuzumab deruxtecan group (Figure 1B and Table 2)</li></ul></li><li>Median progression-free survival in hormone receptor-negative cohort was<ul><li>8.5 months (95% CI, 4.3 to 11.7) in trastuzumab deruxtecan group and</li><li>2.9 months (95% CI, 1.4 to 5.1) in physician&rsquo;s choice group</li></ul></li><li>Hazard ratio was<ul><li>0.46 (95% CI, 0.24 to 0.89) in favor of trastuzumab deruxtecan group (Fig. S3A).</li></ul></li></ul><hr><p><img src=https://i.imgur.com/lKQLn4s.png width=auto alt="Figure 1B: height:350px"></p><hr><a href=#overall-survival><h2 id=overall-survival><span class=hanchor arialabel=Anchor># </span>Overall Survival</h2></a><ul><li>Median overall survival in hormone receptor-positive cohort was<ul><li>23.9 months (95% CI, 20.8 to 24.8) in trastuzumab deruxtecan group and</li><li>17.5 months (95% CI, 15.2 to 22.4) in physician&rsquo;s choice group</li></ul></li><li>Hazard ratio for death was<ul><li>0.64 (95% CI, 0.48 to 0.86; P=0.003) in favor of trastuzumab deruxtecan group (Figure 1C)</li></ul></li><li>Median overall survival among all patients was<ul><li>23.4 months (95% CI, 20.0 to 24.8) in trastuzumab deruxtecan group and</li><li>16.8 months (95% CI, 14.5 to 20.0) in physician&rsquo;s choice group</li></ul></li></ul><hr><ul><li>Hazard ratio was<ul><li>0.64 (95% CI, 0.49 to 0.84; P=0.001) in favor of trastuzumab deruxtecan group (Figure 1D)</li></ul></li><li>P values crossed interim stopping boundary of 0.0075 in both cohorts</li><li>Median overall survival in hormone receptor-negative cohort was<ul><li>18.2 months (95% CI, 13.6 to not evaluable) in trastuzumab deruxtecan group and</li><li>8.3 months (95% CI, 5.6 to 20.6) in physician&rsquo;s choice group</li></ul></li><li>Hazard ratio was<ul><li>0.48 (95% CI, 0.24 to 0.95) in favor of trastuzumab deruxtecan group (Fig. S3B).</li></ul></li></ul><hr><p><img src=https://i.imgur.com/1faZk9s.png width=auto alt="Figure: height:300px"></p><p><img src=https://i.imgur.com/OhUSi0c.png width=auto alt="Figure: height:300px"></p><hr><a href=#objective-response-rate><h2 id=objective-response-rate><span class=hanchor arialabel=Anchor># </span>Objective Response Rate</h2></a><ul><li>Percentage of patients with confirmed objective response in hormone receptor-positive cohort was<ul><li>52.6% (95% CI, 47.0 to 58.0) in trastuzumab deruxtecan group and</li><li>16.3% (95% CI, 11.0 to 22.8) in physician&rsquo;s choice group (Fig. S4 and Table 2)</li></ul></li><li>complete response;<ul><li>3.6% of patients in trastuzumab deruxtecan group and</li><li>0.6% in physician&rsquo;s choice group</li></ul></li><li>progressive disease as the best overall response<ul><li>7.8% patients in trastuzumab deruxtecan group</li><li>21.1% in physician&rsquo;s choice group</li></ul></li><li>Median duration of response was<ul><li>10.7 months in trastuzumab deruxtecan group and</li><li>6.8 months in physician&rsquo;s choice group.</li></ul></li></ul><hr><a href=#objective-response-rate-all-patients><h2 id=objective-response-rate-all-patients><span class=hanchor arialabel=Anchor># </span>Objective Response Rate (All Patients)</h2></a><ul><li>Percentage of patients with confirmed objective response among all patients was<ul><li>52.3% (95% CI, 47.1 to 57.4) in trastuzumab deruxtecan group and</li><li>16.3% (95% CI, 11.3 to 22.5) in physician&rsquo;s choice group (Fig. S4 and Table 2)</li></ul></li><li>In hormone receptor-negative cohort, corresponding percentages were<ul><li>50.0% (95% CI, 33.8 to 66.2) and</li><li>16.7% (95% CI, 3.6 to 41.4).</li></ul></li></ul><hr><a href=#safety-analysis><h2 id=safety-analysis><span class=hanchor arialabel=Anchor># </span>Safety Analysis</h2></a><ul><li>Median duration of treatment was<ul><li>8.2 months (range, 0.2 to 33.3) and</li><li>3.5 months (range, 0.3 to 17.6) in respective groups</li></ul></li><li>99.5% of patients in trastuzumab deruxtecan group and 98.3% in physician&rsquo;s choice group had at least one adverse event that emerged or worsened after initiation of trial drug until 47 days after last dose of trial drug (Table S4)</li><li>Exposure-adjusted incidence rates were 1.30 per patient-year and 2.66 per patient-year, respectively (Table S5)</li></ul><hr><ul><li>Incidence of serious adverse events was<ul><li>27.8% in trastuzumab deruxtecan group and</li><li>25.0% in physician&rsquo;s choice group</li></ul></li><li>Incidence of adverse events of grade 3 or higher was<ul><li>52.6% and 67.4%, respectively</li></ul></li><li>Incidence of adverse events associated with discontinuation of treatment was<ul><li>16.2% in trastuzumab deruxtecan group and</li><li>8.1% in physician&rsquo;s choice group</li></ul></li><li>Incidence of adverse events associated with dose reductions was<ul><li>22.6% and 38.4%, respectively.</li></ul></li></ul><hr><a href=#adverse-events><h2 id=adverse-events><span class=hanchor arialabel=Anchor># </span>Adverse Events</h2></a><ul><li>adverse events associated with death<ul><li>3.8% of patients in trastuzumab deruxtecan group and</li><li>2.9% in physician&rsquo;s choice group</li></ul></li><li>Drug-related deaths in trastuzumab deruxtecan group were due to<ul><li>pneumonitis (in 2 patients [0.5%]) and</li><li>ischemic colitis,</li><li>disseminated intravascular coagulation,</li><li>dyspnea,</li><li>febrile neutropenia,</li><li>sepsis (in 1 patient [0.3%] each)</li></ul></li><li>No drug-related deaths were reported in physician&rsquo;s choice group.</li></ul><hr><a href=#drug-related-adverse-events><h2 id=drug-related-adverse-events><span class=hanchor arialabel=Anchor># </span>Drug-related Adverse Events</h2></a><ul><li><p>most common drug-related adverse events of any grade included nausea (in 73.0% of patients),</p></li><li><p>fatigue (in 47.7%),</p></li><li><p>and alopecia (in 37.7%)</p></li><li><p>These were more frequent than in physician&rsquo;s choice group (in 23.8%, 42.4%, and 32.6%, respectively) (Table 3)</p></li><li><p>In trastuzumab deruxtecan group, most common adverse events of grade 3 or higher were neutropenia (in 13.7% of patients), anemia (in 8.1%), and fatigue (in 7.5%)</p></li><li><p>Corresponding percentages in physician&rsquo;s choice group were 40.7%, 4.7%, and 4.7%.</p></li></ul><hr><p><img src=https://i.imgur.com/3YFxvhe.png width=auto alt="Figure: bg height:650px"></p><hr><a href=#drug-related-interstitial-lung-disease-or-pneumonitis><h2 id=drug-related-interstitial-lung-disease-or-pneumonitis><span class=hanchor arialabel=Anchor># </span>Drug-related Interstitial Lung Disease or Pneumonitis</h2></a><ul><li>Drug-related interstitial lung disease or pneumonitis occurred in 45 patients (12.1%) who received trastuzumab deruxtecan</li><li>13 (3.5%) had a grade 1 event, 24 (6.5%) had a grade 2 event, 5 (1.3%) had a grade 3 event, and 3 (0.8%) had a grade 5 event</li><li>In trastuzumab deruxtecan group, median time to onset in patients with interstitial lung disease or pneumonitis was 129 days (range, 26 to 710)</li><li>Interstitial lung disease or pneumonitis occurred in 1 patient (0.6%) who received physician&rsquo;s choice of chemotherapy; this patient had a grade 1 event while receiving eribulin.</li></ul><blockquote><p>Powell CA, Modi S, Iwata H, et al. Pooled analysis of drug-related interstitial lung disease (ILD) in 8 single-arm trastuzumab deruxtecan (T-DXd) studies. Cancer Res 2021;81:CT167-CT167. abstract.</p></blockquote><hr><a href=#kaplane-meier-analysis-of-time-to-first-adjudicated-drug-related-ildpneumonitis-event><h2 id=kaplane-meier-analysis-of-time-to-first-adjudicated-drug-related-ildpneumonitis-event><span class=hanchor arialabel=Anchor># </span>Kaplane Meier analysis of time to first adjudicated drug-related ILD/pneumonitis event</h2></a><p><img src=https://i.imgur.com/yhdadf7.png width=auto alt="Figure: height:550px"></p><hr><a href=#multivariate-stepwise-cox-regression-analysis><h2 id=multivariate-stepwise-cox-regression-analysis><span class=hanchor arialabel=Anchor># </span>Multivariate stepwise Cox regression analysis</h2></a><p><img src=https://i.imgur.com/ZCX41bG.png width=auto alt="Figure: height:550px"></p><hr><a href=#left-ventricular-dysfunction><h2 id=left-ventricular-dysfunction><span class=hanchor arialabel=Anchor># </span>Left Ventricular Dysfunction</h2></a><ul><li><p>17 patients (4.6%)</p></li><li><p>Decreased ejection fraction of</p><ul><li>grade 1 in 1 patient,</li><li>grade 2 in 14 patients,</li><li>grade 3 in 1 patient and cardiac failure of grade 2 in 1 patient and of grade 3 in 1 patient were reported</li></ul></li><li><p>Grade 2 events (10 to 19% decrease from baseline) were</p><ul><li>in 44 of 371 patients (11.9%) in trastuzumab deruxtecan group and</li><li>in 10 of 172 patients (5.8%) in physician&rsquo;s choice group</li></ul></li><li><p>Grade 3 events (>20% decrease from baseline) were observed in</p><ul><li>5 patients (1.5%) in trastuzumab deruxtecan group and</li><li>no patients in physician&rsquo;s choice group.</li></ul></li></ul><hr><style scoped>h2{font-size:6em;font-weight:700}section{display:flex;justify-content:center;align-items:center}</style><a href=#discussion><h2 id=discussion><span class=hanchor arialabel=Anchor># </span>Discussion</h2></a><hr><a href=#trastuzumab-deruxtecan-vs-chemotherapy><h2 id=trastuzumab-deruxtecan-vs-chemotherapy><span class=hanchor arialabel=Anchor># </span>Trastuzumab Deruxtecan vs. Chemotherapy</h2></a><ul><li>Risk of disease progression or death: 50% lower</li><li>Risk of death: 36% lower</li><li>These results were observed regardless of hormone-receptor status.</li></ul><hr><a href=#her2-status-and-trastuzumab-deruxtecan><h2 id=her2-status-and-trastuzumab-deruxtecan><span class=hanchor arialabel=Anchor># </span>HER2 Status and Trastuzumab Deruxtecan</h2></a><ul><li>HER2-targeted therapies have significantly improved outcomes for patients with HER2-positive breast cancer, but benefits have not yet translated to patients with HER2 expression below this threshold</li><li>Trastuzumab deruxtecan has shown evidence of antitumor activity in cancers across a full range of HER2 expression,<ul><li>due to its enzyme-cleavable antibody-drug linker, high drug-to-antibody ratio, and membrane-permeable payload</li></ul></li><li>In the DESTINY-Breast04 trial,<ul><li>superior activity over standard chemotherapy options in HER2-low</li></ul></li><li>need to redefine subgroups within HER2-negative breast cancers.</li></ul><hr><a href=#trastuzumab-deruxtecan-in-hormone-receptor-positive-her2-negative-breast-cancer><h2 id=trastuzumab-deruxtecan-in-hormone-receptor-positive-her2-negative-breast-cancer><span class=hanchor arialabel=Anchor># </span>Trastuzumab Deruxtecan in Hormone Receptor-Positive, HER2-Negative Breast Cancer</h2></a><ul><li>Real-world data show short progression-free survival after CDK4/6 inhibitor therapy in patients with metastatic hormone receptor-positive, HER2-negative breast cancer</li><li>In the trial, patients in the hormone receptor-positive cohort who received trastuzumab deruxtecan had significantly longer progression-free and overall survival than those who received physician&rsquo;s choice of chemotherapy</li><li>Patients with previous CDK4/6 inhibitor treatment had a similar progression-free survival benefit to patients without previous treatment.</li></ul><hr><a href=#trastuzumab-deruxtecan-vs-sacituzumab-govitecan><h2 id=trastuzumab-deruxtecan-vs-sacituzumab-govitecan><span class=hanchor arialabel=Anchor># </span>Trastuzumab Deruxtecan vs. Sacituzumab Govitecan</h2></a><ul><li><p>SG for triple-negative disease, based on the results of the ASCENT trial,</p><ul><li>progression-free and overall survival benefits over physician&rsquo;s choice of chemotherapy</li></ul></li><li><p>Although the hormone receptor-negative cohort was small in the DESTINY-Breast04 trial,</p><ul><li>the proportion of patients with hormone receptor-negative disease was representative of the prevalence of such disease within the HER2-low population</li></ul></li><li><p>Data are lacking to compare sacituzumab govitecan with trastuzumab deruxtecan</p></li></ul><hr><a href=#safety-profile-of-trastuzumab-deruxtecan><h2 id=safety-profile-of-trastuzumab-deruxtecan><span class=hanchor arialabel=Anchor># </span>Safety Profile of Trastuzumab Deruxtecan</h2></a><ul><li>The safety profile of trastuzumab deruxtecan in the trial was similar to the established safety profile in patients with HER2-positive metastatic breast cancer</li><li>The incidence of adverse events was similar in the two trial groups</li><li>The most common adverse event of grade 3 or higher was neutropenia in both trial groups, but incidences of febrile neutropenia were low</li><li>Most cases of drug-related interstitial lung disease or pneumonitis in the trial were mild or moderate, and the overall incidence was generally consistent with that in previous studies.</li></ul><hr><a href=#interstitial-lung-disease-or-pneumonitis-risk-with-trastuzumab-deruxtecan><h2 id=interstitial-lung-disease-or-pneumonitis-risk-with-trastuzumab-deruxtecan><span class=hanchor arialabel=Anchor># </span>Interstitial Lung Disease or Pneumonitis Risk with Trastuzumab Deruxtecan</h2></a><ul><li>Interstitial lung disease or pneumonitis remains an important risk associated with trastuzumab deruxtecan</li><li>The trial followed current guidelines for surveillance and management, including proactive monitoring of symptoms and imaging to identify potential cases, active management with prompt dose interruption, and early institution of glucocorticoid treatment as recommended to manage the risk and minimize serious outcomes</li><li>Awareness efforts and research on risk factors for interstitial lung disease or pneumonitis are ongoing.</li></ul><hr><a href=#her2-low-status-and-trastuzumab-deruxtecan><h2 id=her2-low-status-and-trastuzumab-deruxtecan><span class=hanchor arialabel=Anchor># </span>HER2-Low Status and Trastuzumab Deruxtecan</h2></a><ul><li>The accuracy of HER2-low scoring has been questioned, but the progression-free survival benefit was observed in patients with IHC 1+ and IHC 2+, ISH-negative disease</li><li>The VENTANA HER2/neu (4B5) IUO Assay system (with ISH testing when applicable) was used in the trial to identify patients with HER2-low status, suggesting that a conventional IHC test can accurately identify patients who may benefit from trastuzumab deruxtecan</li><li>The data from this trial will be used to update labeling of the assay to include a predictive claim for patients with HER2-low breast cancer</li><li>Alternative quantitative methods may be warranted to better select patients for this new therapy, especially as the minimum HER2-expression threshold required for trastuzumab deruxtecan activity is currently being determined in ongoing studies</li><li>These results could have implications for future selection of patients for trastuzumab deruxtecan treatment.</li></ul><blockquote><p>Fernandez AI, Liu M, Bellizzi A, et al. Examination of low ERBB2 protein expression in breast cancer tissue. JAMA Oncol 2022;8:1-4.</p></blockquote><hr><a href=#conclusion-trastuzumab-deruxtecan-vs-physicians-choice-of-chemotherapy><h2 id=conclusion-trastuzumab-deruxtecan-vs-physicians-choice-of-chemotherapy><span class=hanchor arialabel=Anchor># </span>Conclusion: Trastuzumab Deruxtecan vs. Physician&rsquo;s Choice of Chemotherapy</h2></a><ul><li>significantly longer progression-free survival and overall survival with trastuzumab deruxtecan</li><li>The benefit was observed among patients with HER2-low metastatic breast cancer, regardless of hormone-receptor status</li><li>These results have the potential to improve the treatment outcome for more than half of patients historically categorized as having HER2-negative breast cancer.</li></ul><hr><style scoped>h2{font-size:6em;font-weight:700}section{display:flex;justify-content:center;align-items:center}</style><a href=#the-end><h2 id=the-end><span class=hanchor arialabel=Anchor># </span>THE END</h2></a></article><hr><div class=page-end id=footer><div class=backlinks-container><h3>‚Ü©Ô∏è ÂèçÂêëÈÄ£Áµê</h3><ul class=backlinks><li>ü§≠Ê≤íÊúâÊâæÂà∞ÂèçÂêëÈÄ£Áµê</li></ul></div><div><script async src=https://cdn.jsdelivr.net/npm/d3@6.7.0/dist/d3.min.js integrity="sha256-+7jaYCp29O1JusNWHaYtgUn6EhuP0VaFuswhNV06MyI=" crossorigin=anonymous></script><h3>ü§Ø‰∫íÂãïÂúñ</h3><div id=graph-container></div><style>:root{--g-node:var(--secondary);--g-node-active:var(--primary);--g-node-inactive:var(--visited);--g-link:var(--outlinegray);--g-link-active:#5a7282}</style><script src=https://www.physician.tw/js/graph.2d9e48dbe7ea47c0ef1c58296ce14448.js></script></div></div><div><div id=disqus_thread></div><script type=application/javascript>window.disqus_config=function(){},function(){if(["localhost","127.0.0.1"].indexOf(window.location.hostname)!=-1){document.getElementById("disqus_thread").innerHTML="Disqus comments not available by default when the website is previewed locally.";return}var t=document,e=t.createElement("script");e.async=!0,e.src="//physician.disqus.com/embed.js",e.setAttribute("data-timestamp",+new Date),(t.head||t.body).appendChild(e)}()</script><noscript>Please enable JavaScript to view the <a href=https://disqus.com/?ref_noscript>comments powered by Disqus.</a></noscript><a href=https://disqus.com class=dsq-brlink>comments powered by <span class=logo-disqus>Disqus</span></a></div><div id=contact_buttons><footer><p>Êú¨Á∂≤Á´ôÊòØÁî± Hsieh-Ting Lin ‰ª•‚ù§Ô∏è Áî® <a href=https://github.com/jackyzha0/quartz>Quartz</a>ÈÄôÂÄãÈÖ∑Êù±Ë•øÁ®ÆÂá∫‰æÜü™¥ , ¬© 2023</p><p><a href=https://www.buymeacoffee.com/htl.lizard><img src=https://cdn.buymeacoffee.com/buttons/v2/default-yellow.png width=200></a></p><ul><li><a href=https://www.physician.tw/>üè†È¶ñÈ†Å</a></li><li><a href=https://www.facebook.com/Tim.H.Lin>Facebook</a></li><li><a href=https://twitter.com/htlin222>Twitter</a></li><li><a href=https://github.com/htlin222>GitHub</a></li><li><a href=https://htlin.site>Blog</a></li><li><a href=https://medium.com/@hsieh-ting-lin>Medium</a></li></ul></footer></div></div></body></html>